Intracranial Atherosclerotic Disease Market Report : China's Intracranial Atherosclerotic Disease Interventional Procedures Expected to Grow 22% Y-o-Y by 2023

According to YH Research's report on Intracranial Atherosclerotic Disease Market, this report provides the Intracranial Atherosclerotic Disease Market scenario, definitions, classifications, applications, and industry chain structure, while also discussing the development policies and plans as well as the manufacturing processes and cost structures, analysing the Intracranial Atherosclerotic Disease Market's present development status and future market trends. The Intracranial Atherosclerotic Diseases Market also analyses the Intracranial Atherosclerotic Diseases Market from the angles of production and consumption, to the main production regions, the main consumption regions, and the main manufacturers.

Intracranial Atherosclerotic Disease (ICAD) is one of the important causes of ischaemic stroke, and the mechanisms of related stroke include arterial embolism or occlusion caused by plaque rupture, haemodynamic disorders caused by severely stenotic plaques, and branching occlusive disorders caused by intima-media thickening.

Currently, treatment options for ICAD vary depending on the severity of the stenosis and whether or not the patient is experiencing stroke-like symptoms, and the main treatment options include pharmacological as well as interventional therapies. With the prevalence of intracranial atherosclerotic disease increasing every year, the number of people with intracranial atherosclerotic disease in China is growing every year.

Due to its better safety and efficacy, the volume of intracranial atherosclerotic disease interventions is growing rapidly, driven by technological advances and increased affordability, and the volume of intracranial atherosclerotic disease interventions in China is expected to grow by 22% year-on-year in 2023.

With the aging of the population, the number of patients with intracranial atherosclerotic diseases in China is increasing year by year, and the penetration rate of intracranial atherosclerotic disease interventions is increasing, China's intracranial atherosclerotic disease interventions market is expected to grow by 16.9% year-on-year in 2023.

According to YH Research, the global market size of the treatment of intracranial atherosclerotic disease was approximately $5.72 billion in 2023, with a compound annual growth rate (CAGR) of approximately % from 2019-2023, and it is expected to continue to maintain a stable growth trend in the future, and the market size will be close to $10 billion in 2030, with a CAGR of 8.4% over the next six years.

The global pharmaceuticals market size will be approximately $1.47 trillion in 2023, with an expected CAGR of approximately 5% over the next six years. The pharmaceuticals market consists of chemicals and biologics. Biologics will reach $381 billion in 2022. In comparison, the chemical drugs market is expected to increase from $1005.6 billion in 2018 to $1,094.0 billion in 2022. The major drivers of the pharmaceuticals market include increasing demand for healthcare, advancements in pharmaceutical technology and rising prevalence of chronic diseases, and increasing pharmaceutical R&D activities and investments. However, the industry is also facing various challenges such as stringent market regulations, high R&D costs, expiry of drug patents, and declining revenues. Companies need to innovate and adapt to these challenges to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasising the need for pharmaceutical companies to be flexible and responsive to emerging public health needs.


Translated with www.DeepL.com/Translator (free version)